Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
暂无分享,去创建一个
D. Rodeberg | S. Spunt | D. Hawkins | W. Meyer | T. Yock | L. Teot | S. Wolden | B. Shulkin | M. Parisi | G. McCowage | Yueh-Yun Chi | A. Hayes-Jordan | Jing Tian | D. Harrison | L. Mascarenhas | B. Weigel | R. Venkatramani | P. Hingorani
[1] M. Scorsetti,et al. Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. , 2020, The British journal of radiology.
[2] James R. Anderson,et al. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.
[3] James R. Anderson,et al. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. H. van der Lee,et al. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study , 2018, Cancer.
[5] Steve Y. Cho,et al. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. , 2018, Radiology.
[6] W. Reddick,et al. 18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma , 2018, Journal of Nuclear Medicine.
[7] K. McHugh,et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). , 2017, European journal of cancer.
[8] James R. Anderson,et al. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. McHugh,et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review , 2015, BMJ Open.
[10] H. Schoder,et al. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography. , 2014, International journal of radiation oncology, biology, physics.
[11] Allen R. Chen,et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] James R. Anderson,et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] U. Harmenberg,et al. Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma , 2014, BMC Cancer.
[14] Qiyong Ding,et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.
[15] Byung Il Kim,et al. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18 F-FDG PET/CT and MRI , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[16] James R. Anderson,et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group. , 2014, European journal of cancer.
[17] J. Choi,et al. Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters , 2014, Skeletal Radiology.
[18] F. O’Sullivan,et al. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. , 2014, The Journal of bone and joint surgery. American volume.
[19] Soo-Yong Lee,et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma , 2013, Skeletal Radiology.
[20] D. Jeon,et al. Combination of 18F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma , 2013, The Journal of Nuclear Medicine.
[21] Sara M. Federico,et al. Comparison of PET–CT and conventional imaging in staging pediatric rhabdomyosarcoma , 2013, Pediatric blood & cancer.
[22] S. Spunt,et al. Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas , 2013, Pediatric blood & cancer.
[23] C. Leux,et al. 18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas , 2012, Nuclear medicine communications.
[24] S. Dry,et al. 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy , 2012, Clinical Cancer Research.
[25] H. Schöder,et al. Positron Emission Tomography (PET) Response to Initial Chemotherapy and Radiation Therapy (RT) Predicts Local Control in Rhabdomyosarcoma , 2011 .
[26] C. Freeman,et al. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas , 2011, Journal of surgical oncology.
[27] J. Eary,et al. [F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults , 2009, Cancer.
[28] Joel S. Karp,et al. Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.
[29] Roland L Bassett,et al. 18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma , 2009, Journal of Nuclear Medicine.
[30] James R. Anderson,et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] James R. Anderson,et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Hesseling,et al. PROGNOSTIC VALUE OF DAY 14 BLAST PERCENTAGE AND THE ABSOLUTE BLAST INDEX IN BONE MARROW OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2001, Pediatric hematology and oncology.
[33] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[34] A. Huvos,et al. The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* , 1998, The Journal of bone and joint surgery. American volume.
[35] F. Behm,et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] 渡辺 誠,et al. ^ F-Fluorodeoxy-D-glucose と Positron Emission Tomography を用いたガム咀嚼時の咀嚼筋および舌筋活動測定 , 1997 .
[37] S. Ferrari,et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] B Sundell,et al. Soft-tissue sarcomas. , 1979, British medical journal.
[39] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[40] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[41] M. Gelfand,et al. Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging—A prospective trial , 2017, Cancer.
[42] James R. Anderson,et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] L. Ries,et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .
[44] H. Sather,et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.
[45] G. Rosen,et al. Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. , 1984, Cancer investigation.
[46] D.,et al. Regression Models and Life-Tables , 2022 .